Genentech
Genentech
Genentech (/ˈdʒɛnəˌtɛk/), officially known as Genentech, Inc., is a leading biotechnology company that specializes in the research, development, manufacture, and marketing of pharmaceutical products. The company was founded in 1976 by venture capitalist Robert A. Swanson and biochemist Herbert Boyer.
Etymology
The name "Genentech" is a portmanteau of "genetic engineering technology." The company was one of the first to apply genetic engineering in the development of pharmaceuticals, hence the name.
History
Genentech was founded in 1976 in San Francisco, California. The company's first product, human insulin produced by genetically engineered bacteria, was approved by the Food and Drug Administration (FDA) in 1982. Since then, Genentech has developed and marketed a number of groundbreaking drugs, including Herceptin for breast cancer and Avastin for colorectal cancer.
In 2009, Genentech was fully acquired by the Swiss pharmaceutical company Roche, although it continues to operate as a separate entity within the Roche group.
Related Terms
- Biotechnology
- Pharmaceutical
- Robert A. Swanson
- Herbert Boyer
- Genetic engineering
- San Francisco
- California
- Food and Drug Administration
- Herceptin
- Avastin
- Roche
External links
- Medical encyclopedia article on Genentech
- Wikipedia's article - Genentech
This WikiMD dictionary article is a stub. You can help make it a full article.
Languages: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
Urdu,
বাংলা,
తెలుగు,
தமிழ்,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
European
español,
Deutsch,
français,
русский,
português do Brasil,
Italian,
polski